Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized... Inhaled corticosteroids (ICS) and long-acting β(2)-agonists (LABAs) are recommended in patients with asthma that is not well-controlled; however, many patients continue to have inadequately controlled asthma despite this therapy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of internal medicine Pubmed

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.

Download PDF

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.


Abstract

Inhaled corticosteroids (ICS) and long-acting β(2)-agonists (LABAs) are recommended in patients with asthma that is not well-controlled; however, many patients continue to have inadequately controlled asthma despite this therapy.

Loading next page...
 
/lp/pubmed/omalizumab-in-severe-allergic-asthma-inadequately-controlled-with-NHzPTRZiZj

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0003-4819
DOI
10.7326/0003-4819-154-9-201105030-00002
pmid
21536936

Abstract

Inhaled corticosteroids (ICS) and long-acting β(2)-agonists (LABAs) are recommended in patients with asthma that is not well-controlled; however, many patients continue to have inadequately controlled asthma despite this therapy.

Journal

Annals of internal medicine – Pubmed

Published: Jul 18, 2011

References

  • Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
    et al
  • Poor disease control among insured users of high-dose combination therapy for asthma.
  • Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial.
  • Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control.
    et al
  • Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma.
    American Lung Association Asthma Clinical Research Centers
  • Adverse effects of oral corticosteroids in relation to dose in patients with lung disease.
    et al
  • Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    et al
  • The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
    et al
  • Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
    et al
  • Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    et al
  • Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    et al
  • Dynamic balanced randomization for clinical trials.
  • Validation of a standardized version of the Asthma Quality of Life Questionnaire.
  • Measuring quality of life in asthma.
  • Test-based exact confidence intervals for the difference of two binomial proportions.
  • Sample size for Poisson regression.
  • Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.
    et al
  • Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma.
    National Heart, Lung, and Blood Institute